PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 15, 2026Pharmacy0 citationsOpen Access

Evaluating SGLT2 Inhibitors for Type 2 Diabetes: A Review of Effectiveness on Outcomes

Effectiveness of SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Integrative Review of Reviews and Comparative Effectiveness Studies (2020–2025)

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDesislava StanimirovaGPGuenka PetrovaZMZornitsa Mitkova

Discussion

Loading...

Member takes

Overview

Systematic review shows SGLT2 inhibitors improve glycaemic control and cardiovascular events in diabetes, indicating benefits for kidney health.

Key Points

  • To evaluate the effectiveness of SGLT2 inhibitors on glycaemic control, cardiovascular events, and renal function.
  • Conducted a systematic integrative review of literature published from January 2020 to January 2025.
  • Reviewed 48 abstracts and included 27 full-text articles for analysis, including systematic reviews and meta-analyses.
  • Analyzed comparative effectiveness studies focusing on SGLT2 inhibitors and other antidiabetic medications.
  • SGLT2 inhibitors effectively reduce glucose levels with varying magnitudes compared to other antidiabetics.
  • There is a significant reduction in major cardiovascular events and all-cause mortality, especially compared to DPP-4 inhibitors and placebo.
  • SGLT2 inhibitors consistently lower the risk of acute kidney injury and slow the progression of chronic kidney disease.

Cite This Study

Stanimirova et al. (2026) studied this question.

synapsesocial.com/papers/69b606af83145bc643d1ce1ahttps://doi.org/10.3390/pharmacy14020047
View Full Paper
Ask AI
Bookmark
Share